A Comprehensive Guide to Aromatase Inhibitors: Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know that understanding your ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), targets neutrophil serine proteases, key mediators of neutrophilic inflammation. In a phase 3, double-blind trial ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

Off-label uses outside of the drug's formal Food and Drug Administration (FDA) approval can include migraines and other health issues. Researchers continue to investigate ACE inhibitor use in treating ...

The study compared camizestrant in combination with CDK4/6 inhibitor drugs – such as ... to regimens of CDK4/6 inhibitors with aromatase inhibitors like anastrozole or letrozole.

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer. Camizestrant with a CDK 4/6 inhibitor had a ...

The trial evaluated the efficacy of imlunestrant, an oral selective estrogen receptor degrader (SERD), compared with fulvestrant (Faslodex) in patients who had previously been treated with CDK4/6 ...